Lutz Naehrlich

2.8k total citations
72 papers, 1.1k citations indexed

About

Lutz Naehrlich is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Epidemiology. According to data from OpenAlex, Lutz Naehrlich has authored 72 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Pulmonary and Respiratory Medicine, 15 papers in Surgery and 9 papers in Epidemiology. Recurrent topics in Lutz Naehrlich's work include Cystic Fibrosis Research Advances (48 papers), Neonatal Respiratory Health Research (21 papers) and Tracheal and airway disorders (13 papers). Lutz Naehrlich is often cited by papers focused on Cystic Fibrosis Research Advances (48 papers), Neonatal Respiratory Health Research (21 papers) and Tracheal and airway disorders (13 papers). Lutz Naehrlich collaborates with scholars based in Germany, United States and United Kingdom. Lutz Naehrlich's co-authors include Burkhard Tümmler, Isabelle Sermet‐Gaudelus, Silke van Koningsbruggen‐Rietschel, Jochen G. Mainz, Pierre‐Régis Burgel, Carla Colombo, Cho‐Ming Chao, Kevin W Southern, Silvia Gärtner and B. Wiedemann and has published in prestigious journals such as PLoS ONE, American Journal of Respiratory and Critical Care Medicine and Scientific Reports.

In The Last Decade

Lutz Naehrlich

65 papers receiving 1.1k citations

Peers

Lutz Naehrlich

PRM

SURGE

EPIDE

OTORH

Amparo Escribano Spain

Rita Padoan Italy

Mirjam Stahl Germany

George M. Solomon United States

Noreen Henig United States

Malena Cohen‐Cymberknoh Israel

Deepika Polineni United States

Eric Anderson United States

Luke W. Garratt Australia

James A. Turner United States

Amparo Escribano Spain

Lutz Naehrlich

1.1k ×1.3

PRM

185 ×1.1

SURGE

260 ×1.8

EPIDE

125 ×1.0

47 ×0.5

OTORH

Citations per year, relative to Lutz Naehrlich Lutz Naehrlich (= 1×) peers Amparo Escribano

Countries citing papers authored by Lutz Naehrlich

Since Specialization

Citations

This map shows the geographic impact of Lutz Naehrlich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lutz Naehrlich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lutz Naehrlich more than expected).

Fields of papers citing papers by Lutz Naehrlich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lutz Naehrlich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lutz Naehrlich. The network helps show where Lutz Naehrlich may publish in the future.

Co-authorship network of co-authors of Lutz Naehrlich

This figure shows the co-authorship network connecting the top 25 collaborators of Lutz Naehrlich. A scholar is included among the top collaborators of Lutz Naehrlich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lutz Naehrlich. Lutz Naehrlich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sermet‐Gaudelus, Isabelle, Annalisa Orenti, Elpis Hatziagorou, et al.. (2025). Health inequity in people with cystic fibrosis: can we close the gap?. Annals of the American Thoracic Society. 23(2). 228–240.

Kerem, Eitan, et al.. (2024). Cystic fibrosis in Europe: improved lung function and longevity – reasons for cautious optimism, but challenges remain. European Respiratory Journal. 63(3). 2301241–2301241. 15 indexed citations

Bower, Julie K., Cherry Yin‐Yi Chang, Anna Chin, et al.. (2024). WS01.04 Real-world outcomes in people with cystic fibrosis (pwCF) treated with elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) with up to three years of follow-up. Journal of Cystic Fibrosis. 23. S2–S2. 1 indexed citations

Stahl, Mirjam, Jobst Roehmel, Monika Eichinger, et al.. (2024). Long-Term Impact of Lumacaftor/Ivacaftor Treatment on Cystic Fibrosis Disease Progression in Children 2–5 Years of Age Homozygous for F508del-CFTR : A Phase 2, Open-Label Clinical Trial. Annals of the American Thoracic Society. 21(11). 1550–1559. 5 indexed citations

Naehrlich, Lutz, et al.. (2023). Drug desensitization to lumacaftor/ivacaftor: A fast lane to drug tolerance. Journal of Cystic Fibrosis. 22(5). 941–943. 1 indexed citations

Eickmeier, Olaf, et al.. (2023). WS10.05 Reduction of pulmonary exacerbations in people with cystic fibrosis in Germany between 2019 and 2022. Journal of Cystic Fibrosis. 22. S21–S21. 1 indexed citations

Sutharsan, Sivagurunathan, Folke Brinkmann, Helmut Ellemunter, et al.. (2023). 293 Impact of elexacaftor-tezacaftor-ivacaftor on lung function, nutritional status, pulmonary exacerbation, and sweat chloride in people with cystic fibrosis: real-world evidence from German Cystic Fibrosis Registry. Journal of Cystic Fibrosis. 22. S147–S148.

Stahl, Mirjam, Jobst Roehmel, Monika Eichinger, et al.. (2023). Effects of Lumacaftor/Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 through 5 Years of Age Homozygous for F508del-CFTR : A Phase 2 Placebo-controlled Clinical Trial. Annals of the American Thoracic Society. 20(8). 1144–1155. 13 indexed citations

Sawicki, Gregory S., Mark Chilvers, John McNamara, et al.. (2022). A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant. Journal of Cystic Fibrosis. 21(4). 675–683. 10 indexed citations

10.

Naehrlich, Lutz, et al.. (2020). Risk factors for respiratory Aspergillus fumigatus in German Cystic Fibrosis patients and impact on lung function. Scientific Reports. 10(1). 18999–18999. 34 indexed citations

11.

Davies, Jane C., Isabelle Sermet‐Gaudelus, Lutz Naehrlich, et al.. (2020). A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation. Journal of Cystic Fibrosis. 20(1). 68–77. 44 indexed citations

12.

Hengst, Meike, Lutz Naehrlich, Poornima Mahavadi, et al.. (2018). Hermansky-Pudlak syndrome type 2 manifests with fibrosing lung disease early in childhood. Orphanet Journal of Rare Diseases. 13(1). 42–42. 37 indexed citations

13.

Graeber, Simon Y., Christian Dopfer, Lutz Naehrlich, et al.. (2018). Effects of Lumacaftor–Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine. 197(11). 1433–1442. 83 indexed citations

14.

Räth, Timo, et al.. (2014). Identification of Neutrophil Activation Markers as Novel Surrogate Markers of CF Lung Disease. PLoS ONE. 9(12). e115847–e115847. 13 indexed citations

15.

Räth, Timo, Roman Zachoval, Lutz Naehrlich, et al.. (2013). Serum Proteome Profiling Identifies Novel and Powerful Markers of Cystic Fibrosis Liver Disease. PLoS ONE. 8(3). e58955–e58955. 30 indexed citations

16.

Naehrlich, Lutz, Manfred Ballmann, Jane C. Davies, et al.. (2013). Nasal potential difference measurements in diagnosis of cystic fibrosis: An international survey. Journal of Cystic Fibrosis. 13(1). 24–28. 31 indexed citations

17.

Thomas, Muriel, Lydie Lemonnier, Vincent Gulmans, et al.. (2013). Is there evidence for correct diagnosis in cystic fibrosis registries?. Journal of Cystic Fibrosis. 13(3). 275–280. 13 indexed citations

18.

Naehrlich, Lutz, et al.. (2012). Misdiagnosis of cystic fibrosis — Experience from Germany. Journal of Cystic Fibrosis. 12(1). 68–73. 11 indexed citations

19.

Mainz, Jochen G., et al.. (2010). Prevalence of CF-related chronic rhinosinusitis – results from a multicentre interdisciplinary study. Journal of Cystic Fibrosis. 9. S118–S118. 5 indexed citations

20.

Kraus, Cornelia, et al.. (2007). Effect of Cardioactive Drugs on Action Potential Generation and Propagation in Embryonic Stem Cell-Derived Cardiomyocytes. Cellular Physiology and Biochemistry. 19(5_6). 239–248. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact